Form 4: Boston Scientific Executive Sells Shares Under Pre-Arranged Trading Plan

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, sold 14,132 shares of common stock at $80 per share on August 28, 2024, under a pre-established Rule 10b5-1 trading plan.

Summary

• On August 28, 2024, Joseph Michael Fitzgerald, an Executive Vice President and Group President of Cardiology at Boston Scientific, sold 14,132 shares of Boston Scientific common stock.
• The sale was executed at a price of $80 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.
• Following the transaction, Fitzgerald directly owns 176,355 shares of Boston Scientific common stock.
• Fitzgerald also has indirect ownership of 4,894 shares held by his child, but he disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine stock sale under a pre-arranged plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often executed under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The market typically views these sales in the context of the executive's overall holdings and the reasons behind the sale (e.g., diversification, personal expenses).

Stakeholder Impact

• The sale could have a minor impact on shareholders if it is perceived negatively, but given the pre-planned nature and the executive's continued significant holdings, the impact is likely minimal.

Key Dates